Black Friday

All the Features.
Half the Price.

$149.00 / first year $299.50

Then $299.50/year

Last Close
0.8084
Nov 18 • 3:59 PM ET Dollar change+0.1604 Percentage change(24.75%)
Aftermarket Close
0.8084
Aftermarket • 4:00 PM ET Dollar change0.0000 Percentage change(0.00%)
Today, 2:04 PMNo clear catalyst identified for TLSA's 26% regular-session advance
Index
-
Market Cap
103.73M
Enterprise Value
101.48M
Income
-25.19M
Sales
0.00M
Book/sh
-0.02
Cash/sh
0.02
Dividend Est.
-
Dividend TTM
-
Dividend Ex-Date
-
Dividend Gr. 3/5Y
- -
Payout
-
Employees
10
IPO
Nov 20, 2018
P/E
-
Forward P/E
-
PEG
-
P/S
-
P/B
-
P/C
32.62
P/FCF
-
EV/EBITDA
-
EV/Sales
-
Quick Ratio
0.69
Current Ratio
0.69
Debt/Eq
-
LT Debt/Eq
-
Option/Short
Yes / Yes
EPS (ttm)
-0.20
EPS next Y
-0.19
EPS next Q
-
EPS this Y
-8.23%
EPS next Y
-8.93%
EPS next 5Y
-6.24%
EPS past 3/5Y
-0.89% -0.19%
Sales past 3/5Y
- -
EPS Y/Y TTM
-78.92%
Sales Y/Y TTM
-
EPS Q/Q
-101.04%
Sales Q/Q
-
Insider Own
49.84%
Insider Trans
1.57%
Inst Own
3.12%
Inst Trans
-17.56%
ROA
-178.26%
ROE
-780.60%
ROIC
-
Gross Margin
-
Oper. Margin
-
Profit Margin
-
SMA20
9.39%
SMA50
-10.67%
SMA200
-29.86%
Trades
Shs Outstand
128.03M
Shs Float
64.36M
52W High
1.90 -57.45%
52W Low
0.55 46.90%
Volatility
13.20% 11.85%
ATR (14)
0.09
RSI (14)
52.41
Beta
0.52
Rel Volume
1.92
Avg Volume
663.33K
Volume
1,274,385
Perf Week
30.18%
Perf Month
-19.96%
Perf Quarter
-27.82%
Perf Half Y
-49.79%
Perf YTD
-45.74%
Perf Year
-54.33%
Perf 3Y
43.87%
Perf 5Y
-43.86%
Perf 10Y
-
Prev Close
0.65
Price
0.81
Change %
24.75%
Consensus
Strong Buy
Avg. Price Target
$7.99
Implied Upside
+888.4%
Analysts3incl. previous ratings
Rating Distribution3 Buy · 0 Hold · 0 Sell
DateActionAnalystRating ChangePrice Target ChangeImplied Upside
Sep 03, 2026Initiated
BBTIG Research
Buy$7+765.9%
Dec 22, 2020Initiated
RILY logoRB. Riley Securities
Buy$8+889.6%
Dec 17, 2018Initiated
LLaidlaw
Buy
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Elrifi IvorChief Executive OfficerAug 05 '26Buy1.00237,616237,6164,793,684Aug 06 09:30 AM
Elrifi IvorChief Executive OfficerAug 04 '26Buy0.9783,80781,2934,556,068Aug 06 09:30 AM
Elrifi IvorChief Executive OfficerAug 03 '26Buy1.00667,000667,0004,472,261Aug 05 04:30 PM
Tiziana Life Sciences Ltd. is a clinical-stage biotechnology company, which engages in developing therapies for neurodegenerative and lung diseases. Its clinical pipeline includes drug assets for Secondary Progressive Multiple Sclerosis, Amyotrophic Lateral Sclerosis, and Alzheimer's. The company was founded by Gabriele Marco Antonio Cerrone on February 11, 1998 and is headquartered in London, the United Kingdom.
Founder & Executive ChairmanMr. Gabriele Marco Antonio Cerrone M.B.A.
COO & CFOMs. Keeren Shah
CEO & Executive DirectorDr. Ivor R. Elrifi Ph.D.
Chief Regulatory OfficerMr. William Edward Tente M.S.
Chief Medical OfficerDr. Richard K. Kim M.D.